Axa S.A. Increases Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Axa S.A. grew its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 274.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 873,217 shares of the company’s stock after acquiring an additional 639,855 shares during the quarter. Axa S.A. owned about 1.77% of Cryoport worth $6,034,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its position in shares of Cryoport by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 366,031 shares of the company’s stock valued at $5,670,000 after buying an additional 12,008 shares during the last quarter. Thematics Asset Management grew its holdings in shares of Cryoport by 19.5% during the fourth quarter. Thematics Asset Management now owns 749,000 shares of the company’s stock worth $11,602,000 after purchasing an additional 122,000 shares during the last quarter. Natixis Investment Managers International increased its position in shares of Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after purchasing an additional 1,727 shares in the last quarter. Cadian Capital Management LP lifted its holdings in shares of Cryoport by 30.4% in the 4th quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock valued at $53,659,000 after purchasing an additional 807,340 shares during the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in shares of Cryoport in the 4th quarter valued at about $665,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on CYRX shares. Jefferies Financial Group lowered Cryoport from a “buy” rating to a “hold” rating and cut their price target for the stock from $20.00 to $8.00 in a research report on Wednesday, August 7th. B. Riley upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and reduced their price target for the company from $19.00 to $15.00 in a research report on Wednesday, July 31st. UBS Group lowered their price objective on shares of Cryoport from $17.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Needham & Company LLC dropped their price objective on shares of Cryoport from $18.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Cryoport presently has a consensus rating of “Hold” and an average price target of $11.60.

Cryoport Stock Up 0.4 %

CYRX stock opened at $8.00 on Friday. Cryoport, Inc. has a one year low of $5.32 and a one year high of $20.10. The company has a debt-to-equity ratio of 0.97, a quick ratio of 7.99 and a current ratio of 8.38. The company has a fifty day moving average of $8.51 and a 200-day moving average of $11.29. The stock has a market capitalization of $394.06 million, a PE ratio of -3.24 and a beta of 1.60.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.25). The business had revenue of $57.60 million during the quarter, compared to analysts’ expectations of $57.65 million. Cryoport had a negative net margin of 76.48% and a negative return on equity of 15.55%. Cryoport’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.42) EPS. As a group, analysts expect that Cryoport, Inc. will post -1.63 EPS for the current year.

Cryoport announced that its board has initiated a share buyback plan on Tuesday, August 6th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase up to 49.1% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Cryoport news, Director Ramkumar Mandalam sold 4,167 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.04, for a total value of $33,502.68. Following the completion of the sale, the director now owns 56,032 shares of the company’s stock, valued at $450,497.28. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 7,167 shares of company stock valued at $60,363 over the last quarter. Company insiders own 10.10% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.